Shattuck Labs (Shattuck Labs) Total Liabilities : $17.52 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Shattuck Labs Total Liabilities?

Shattuck Labs's Total Liabilities for the quarter that ended in Mar. 2024 was $17.52 Mil.

Shattuck Labs's quarterly Total Liabilities declined from Sep. 2023 ($17.67 Mil) to Dec. 2023 ($14.86 Mil) but then increased from Dec. 2023 ($14.86 Mil) to Mar. 2024 ($17.52 Mil).

Shattuck Labs's annual Total Liabilities increased from Dec. 2021 ($26.80 Mil) to Dec. 2022 ($29.17 Mil) but then declined from Dec. 2022 ($29.17 Mil) to Dec. 2023 ($14.86 Mil).

Shattuck Labs Total Liabilities Historical Data

The historical data trend for Shattuck Labs's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shattuck Labs Total Liabilities Chart

Shattuck Labs Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

79.52

39.13

26.80

29.17

14.86

Shattuck Labs Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															20.02	16.81	17.67	14.86	17.52

Shattuck Labs Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Shattuck Labs's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11.453	+	(3.406	+	4.4408920985006E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	14.86

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	159.564	-	144.705
	=	14.86

Shattuck Labs's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	14.329	+	(3.193	+	-2.2204460492503E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	17.52

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	146.335	-	128.813
	=	17.52

Shattuck Labs Total Liabilities Related Terms

Thank you for viewing the detailed overview of Shattuck Labs's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Shattuck Labs (Shattuck Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shattuck Labs Inc (NAS:STTK) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 W. 5th Street, Suite 1200, Austin, TX, USA, 78701

Website

https://www.shattucklabs.com

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

Executives

Andrew R Neill	officer: See Remarks	1018 W 11TH STREET, SUITE 100, AUSTIN TX 78703
Stephen Stout	officer: See Remarks	C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
George Golumbeski	director	C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Abhinav A. Shukla	officer: Chief Technical Officer	500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
Carrie Brownstein	director	500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701
Erin Ator Thomson	officer: General Counsel	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Josiah Hornblower	director, 10 percent owner, officer: Chairman	3317 BOWMAN AVE, AUSTIN TX 78703
Taylor Schreiber	director, officer: Chief Executive Officer	100 EUROPA DRIVE, CHAPEL HILL NC 27517
Redmile Group, Llc	director, 10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Helen M Boudreau	director	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Neil W Gibson	director	C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Tyler Brous	director	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Casi Deyoung	officer: Chief Business Officer	C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744
Arundathy N. Pandite	officer: Chief Medical Officer	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Victor Stone	director	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703